Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed
Abstract
Background: In the DELIVER trial, eptinezumab administration was associated with sustained reductions in headache frequency and migraine-related impact in participants for whom previous preventive treatments have failed. This post hoc analysis evaluated long-term maintenance of initial ≥ 50% and ≥ 75% migraine response.
Methods: DELIVER was a 24-week, randomized, double-blind, placebo-controlled trial with a 48-week dose-blinded extension. For participants with initial ≥ 50% or ≥ 75% reduction in monthly migraine days-defined as response following their first dose (Weeks 1-12) or first and second dose (Weeks 1-24)-maintenance of ≥ 50% or ≥ 75% migraine response was assessed for each subsequent 12-week dosing interval. Proportions of severe migraine attacks, 6-Item Headache Impact Test (HIT-6) total score, migraine-specific Work Productivity and Activity Impairment (WPAI:M) presenteeism subscore, and Patient Global Impression of Change (PGIC) categories were also evaluated in Weeks 1-12 responders.
Results: Of participants with ≥ 50% migraine response over Weeks 1-12, 61.0% (69/113, 100 mg) and 73.8% (93/126, 300 mg) maintained response over the entire 72-week treatment period; ≥ 50% responders (Weeks 1-24) and ≥ 75% responders (Weeks 1-12 and 1-24) showed similar trends. Weeks 1-12 responders (≥ 50% and ≥ 75%) experienced sustained reductions in migraine severity, HIT-6 total score, and presenteeism subscore, with most reporting improvements per the PGIC.
Conclusions: For…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.